All News

Found 1,089 articles

• Editas Medicine Strengthens Board of Directors with Appointment of New Chair and New Director

  4/13/2023

  Editas Medicine, Inc. today announced the appointment of current Independent Director Emma Reeve as Chair of the Board, effective at the Company’s next annual stockholder meeting, currently scheduled for June 1.

• HI-Bio Announces Positive Phase 2 Data on Felzartamab for the Treatment of Primary Membranous Nephropathy

  4/11/2023

  Human Immunology Biosciences announced positive data from two Phase 2 studies of felzartamab, M-PLACE and NewPLACE.

• MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

  3/15/2023

  MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2022.

• Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023

  3/14/2023

  Incyte (Nasdaq:INCY) today announced that multiple abstracts from across its oncology portfolio will be presented during the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, held April 14-19, in Orlando, Florida.

• Invitation to MorphoSys' Full Year Results 2022 Conference Call on March 16, 2023

  3/9/2023

  MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the financial year 2022 on March 15, 2023 at 09:00 pm CET (08:00 pm GMT; 04:00 pm EDT).

• 

  MorphoSys Cuts Pre-Clinical Programs, 17% of Staff

  3/2/2023

  MorphoSys AG announced Thursday it plans to drop its pre-clinical programs and cut 17% of its workforce in an effort to extend its cash runway. 

• MorphoSys Stops Work and Operations on Pre-Clinical Research Programs

  3/2/2023

  MorphoSys AG announced that the company will stop work and operations on its pre-clinical research programs to optimize its cost structure.

• Ad hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters

  3/2/2023

  MorphoSys AG announces that it will stop work and operations on its pre-clinical research programs to optimize its cost structure.

• Xencor Reports Fourth Quarter and Full Year 2022 Financial Results

  2/23/2023

  Xencor, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a review of recent business and clinical highlights.

• Vir Biotechnology Appoints Sung Lee as Chief Financial Officer

  2/16/2023

  Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Sung Lee as Executive Vice President and Chief Financial Officer (CFO), effective March 27, 2023.

• Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs

  2/7/2023

  Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs.

• Full-Life Technologies Announces Appointment of Steffen Heeger, MD, PhD, as Chief Medical Officer and Fa Liu, PhD, as Chief Scientific Officer

  1/16/2023

  Full-Life Technologies today announced the appointments of Steffen Heeger, MD, PhD, as Chief Medical Officer (CMO) and Fa Liu, PhD as Chief Scientific Officer (CSO).

• MorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024

  1/9/2023

  MorphoSys AG announced that topline data from the ongoing Phase 3 MANIFEST-2 study - a global, randomized, double-blind clinical trial exploring pelabresib, an investigational BET inhibitor, in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis - are expected to be available in early 2024.

• MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability

  1/5/2023

  MorphoSys AG reported preliminary Monjuvi ® U.S. net product sales for the full year of 2022 and provided its financial guidance for 2023.

• InnoCare Announces Approval of Tafasitamab in Combination With Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Hong Kong

  12/28/2022

  InnoCare Pharma announced the approval of tafasitamab in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplant by the Department of Health, the Hong Kong Special Administrative Region, China.

• InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Orelabrutinib in Combination with Tafasitamab + Lenalidomide in China

  12/20/2022

  InnoCare Pharma (HKEX: 09969; SSE: 688428) announced today that the Company has received approval from the Center for Drug Evaluation (CDE) to conduct a single-arm, open-label, multi-cohort phase II clinical trial evaluating the efficacy and safety of orelabrutinib in combination with tafasitamab + lenalidomide for the treatment of patients with relapsed or refractory Non-Hodgkin's lymphoma (NHL).

• HOOKIPA Pharma Appoints Katia Schlienger, M.D., Ph.D., Chief Medical Officer and Malte Peters, M.D., to Board of Directors

  12/15/2022

  HOOKIPA Pharma Inc. announced today the promotion of Katia Schlienger, M.D., Ph.D., to Chief Medical Officer and the appointment of Malte Peters, M.D., to its Board of Directors, both effective January 1, 2023.

• Alternative Bio Launches with USD 15M Series Seed Financing Led by Eight Roads Ventures with F-Prime Capital and Sequoia China Seed Fund

  12/15/2022

  Alternative Bio Inc., a privately held biotechnology company developing novel therapeutics targeting a previously untapped class of post-translational modifying enzymes announced its $15 million Series Seed financing co-led by Eight Roads Ventures with F-Prime Capital and Sequoia China Seed Fund.

• Foresight Diagnostics Announces Three Presentations Highlighting Clinical Studies Using Patented PhasED-Seq® MRD Platform at the 64th American Society of Hematology Annual Meeting and Exposition

  11/29/2022

  Foresight Diagnostics, a leader in minimal residual disease (MRD) detection technology, announced today that three studies utilizing their patented PhasED-Seq technology will be presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH 2022) taking place December 10-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, LA.

• MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results

  11/16/2022

  MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the third quarter and the first nine months of 2022.